-  Monoclonal antibody against HER-2/neu cell membrane receptor

-  Aus $50,000 per course, PBS covered if

-  Late stage metastatic breast Ca (beyond axillary nodes)

-  Early stage breast Ca post Sx w LVEF >45% & no S/S heart failure

-  Increased survival & response rate in metastatic HER2+ breast Ca

-  +/-70% fail to respond, resistance develops rapidly

-  Generally used for 1yr



-  Adjuvant Mx of HER-2 receptor positive breast cancer

-  Human Epidermal Growth Factor Receptor 2


Side Effects

-  Cardiac dysfunction 2-7% pts: Echo pre Mx

-  Fever, nausea, vomiting, diarrhoea, rash

-  Cough, headache, fatigue, SOB

-  Leukopaenia, anaemia